Grifols (GRFS) Invested Capital (2009 - 2025)
Grifols (GRFS) posted Invested Capital of $17.4 billion for Q4 2025, up 138.32% quarter-over-quarter from $7.3 billion in Q4 2024, and up 138.32% year-on-year from $7.3 billion in Q4 2024.
Grifols (GRFS) Invested Capital (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Invested Capital for 16 consecutive years, with $17.4 billion the latest figure, recorded in Q4 2025.
- Invested Capital for Q4 2025 came in at $17.4 billion, up 138.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.4 billion (up 138.32% YoY), and the FY2025 annual result was $17.4 billion, up 1689.62% from the prior year.
- Invested Capital was $17.4 billion for Q4 2025 at Grifols, up from $7.3 billion in the prior quarter.
- Over five years, Invested Capital peaked at $20.0 billion in Q4 2023 and troughed at $7.3 billion in Q4 2024.
- Average Invested Capital over 5 years is $16.7 billion, with a median of $19.1 billion recorded in 2022.
- Year-over-year, Invested Capital soared 149.24% in 2021 and slumped 63.54% in 2024.
- Over 5 years, Invested Capital stood at $19.5 billion in 2021, then decreased by 2.1% to $19.1 billion in 2022, then rose by 4.53% to $20.0 billion in 2023, then plunged by 63.54% to $7.3 billion in 2024, then surged by 138.32% to $17.4 billion in 2025.
- Per Business Quant data, the three most recent Invested Capital figures were $17.4 billion in Q4 2025, $7.3 billion in Q4 2024, and $20.0 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 72.79 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 98.65 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -6.66 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 48.32 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 66.51 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 45.69 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 90.96 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -19.00 Mn |
| 10 | Grifols | - | - | - | 17.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.36 Bn |
| Dec 31, 2024 | 7.28 Bn |
| Dec 31, 2023 | 19.98 Bn |
| Dec 31, 2022 | 19.11 Bn |
| Dec 31, 2021 | 19.52 Bn |
| Dec 31, 2020 | 7.83 Bn |
| Dec 31, 2019 | 15.56 Bn |
| Dec 31, 2018 | 12.64 Bn |
| Dec 31, 2017 | 11.41 Bn |
| Dec 31, 2016 | 9.36 Bn |
| Dec 31, 2015 | 3.91 Bn |
| Dec 31, 2014 | 3.57 Bn |
| Dec 31, 2013 | 3.21 Bn |
| Sep 30, 2013 | 2.77 Bn |
| Jun 30, 2013 | 2.69 Bn |
| Mar 31, 2013 | 2.72 Bn |
| Dec 31, 2012 | 2.69 Bn |
| Sep 30, 2012 | 2.45 Bn |
| Jun 30, 2012 | 2.48 Bn |
| Mar 31, 2012 | 2.31 Bn |